Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

In brief: Truvada for HIV prevention.

[No authors listed]

Med Lett Drugs Ther. 2012 Aug 6;54(1396):63-4. Review. No abstract available.

PMID:
22869292
2.

Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.

[No authors listed]

AIDS Patient Care STDS. 2010 Jun;24(6):395-6. No abstract available.

PMID:
20575158
3.

HIV/AIDS clinical trials. A powerful and perplexing new HIV prevention tool.

Cohen J.

Science. 2010 Dec 3;330(6009):1298-9. doi: 10.1126/science.330.6009.1298. No abstract available.

PMID:
21127220
4.

AIDS research. Complexity surrounds HIV prevention advances.

Cohen J.

Science. 2011 Jul 22;333(6041):393. doi: 10.1126/science.333.6041.393. No abstract available.

PMID:
21778370
5.

New once-a-day drugs: Truvada and Epzicom.

Berger DS.

Posit Aware. 2004 Nov-Dec;15(6):38-9. No abstract available.

PMID:
15619773
6.

Trial will evaluate a once-daily dose of raltegravir.

[No authors listed]

AIDS Patient Care STDS. 2008 Nov;22(11):918-9. No abstract available.

PMID:
19043842
7.

Gay community to test HIV prevention pill.

Bateman C.

S Afr Med J. 2008 Sep;98(9):660-1. No abstract available.

PMID:
19113040
8.

Preexposure prophylaxis for HIV infection.

Steinbrook R.

JAMA. 2012 Sep 5;308(9):865-6. doi: 10.1001/jama.2012.9885. No abstract available.

PMID:
22820712
9.

FDA PrEPares to reduce risk of HIV infection with Truvada®.

Breeze S.

Expert Rev Clin Pharmacol. 2012 Sep;5(5):499. No abstract available.

PMID:
23272332
10.

PrEP trial in women halted due to doubts that it could show efficacy.

McEnery R.

IAVI Rep. 2011 Mar-Apr;15(2):21. No abstract available.

11.

Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges?

Curran JW, Crosby RA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S163-6. doi: 10.1016/j.amepre.2012.10.005. No abstract available.

PMID:
23253761
12.

Pre-exposure prophylaxis for HIV: can it be implemented in the real world?

Katz MH.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S161-2. doi: 10.1016/j.amepre.2012.10.004. No abstract available.

PMID:
23253760
13.

The new revolution: HIV prevention in a pill.

Grant R.

Posit Aware. 2013 Summer;25(5):2-5. No abstract available.

PMID:
25358197
14.

Infectious diseases. Doubts dispelled about HIV prevention.

Cohen J.

Science. 2015 Mar 6;347(6226):1055-6. doi: 10.1126/science.347.6226.1055. No abstract available.

PMID:
25745140
15.

From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation.

Warren MJ, Bass ES.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S167-70. doi: 10.1016/j.amepre.2012.10.006. No abstract available.

PMID:
23253762
16.

CDC promotes pre-exposure prophylaxis for HIV prevention.

Roehr B.

BMJ. 2014 May 19;348:g3384. doi: 10.1136/bmj.g3384. No abstract available.

PMID:
24841703
17.

Early end for FEM-PrEP HIV prevention trial.

[No authors listed]

AIDS Patient Care STDS. 2011 Jun;25(6):383. doi: 10.1089/apc.2011.9874. No abstract available.

PMID:
21612547
18.

Truvada for HIV prophylaxis in heterosexual patients.

DeDea L.

JAAPA. 2012 Oct;25(10):14. No abstract available.

PMID:
23115862
19.

Second complete once-daily single tablet therapy in development.

[No authors listed]

AIDS Patient Care STDS. 2009 Aug;23(8):680. No abstract available.

PMID:
19694037
20.

A truvada hypersensitivity reaction simulating abacavir hypersensitivity.

de Perio MA, Gomez FJ, Frame PT, Fichtenbaum CJ.

AIDS. 2007 Oct 18;21(16):2252-3. No abstract available.

PMID:
18090057
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk